Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059432 | 0.85 | KDM4E (0.47) | ALDH1A1KDM4EHSD17B10DHODHSMN1; SMN2 | |
| SCHEMBL6628232 | 0.83 | KDM4E (0.46) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HTT | |
| SCHEMBL3881739 | 0.83 | LMNA (0.56) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL3768853 | 0.82 | KDM4E (0.45) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HTT | |
| SCHEMBL25820060 | 0.81 | GAA (0.45) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HTT | |
| SCHEMBL1366357 | 0.80 | CYP1A2 (0.62) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL26649440 | 0.80 | POLB (0.40) | ALDH1A1KDM4EDHODHGAAMPO | |
| SCHEMBL29868726 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10DHODHSMN1; SMN2 | |
| SCHEMBL28877520 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10DHODHSMN1; SMN2 | |
| SCHEMBL3906125 | 0.77 | GAA (0.47) | ALDH1A1KDM4EHSD17B10DHODHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219456-A1 | QUINOLINE-BASED HISTONE DEACETYLASE INHIBITORY SUBSTANCES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS ACTIVE INGREDIENT | 숙명여자대학교 산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| CN-109776407-B | Preparation method of 2-methyl-4-hydroxymethyl quinoline and derivatives thereof | 济南大学 | 2022-04-12 | — | — | CN | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | ALDH1A1 1468/4885KDM4E 2703/4885HSD17B10 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.